140 related articles for article (PubMed ID: 31294640)
1. Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
Hickey E; Clemons B; Griffin S; Cox J; Sutphin S; Ramlal R; Benitez L
Leuk Lymphoma; 2019 Dec; 60(14):3557-3560. PubMed ID: 31294640
[No Abstract] [Full Text] [Related]
2. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
3. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
6. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Zhu HH; Hu J; Lo-Coco F; Jin J
Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
[TBL] [Abstract][Full Text] [Related]
7. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
8. Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
Norsworthy KJ; Avagyan A; Bird ST; Li Y; Akhtar S; Liao J; Wernecke M; Deisseroth AB; Chuk M; MaCurdy TE; Swain R; Kelman JA; Farrell AT; de Claro RA; Pazdur R; Blumenthal G; Graham DJ
Leukemia; 2020 Nov; 34(11):3082-3084. PubMed ID: 32518418
[No Abstract] [Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
10. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R; Ades L; Thomas X; Guerci-Bresler A; Pigneux A; Vey N; Raffoux E; Castaigne S; Spertini O; Wittnebel S; Marolleau JP; Damaj G; Bordessoule D; Lejeune J; Chevret S; Fenaux P
Haematologica; 2018 Nov; 103(11):e519-e521. PubMed ID: 29794147
[No Abstract] [Full Text] [Related]
11. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
Strocchio L; Gurnari C; Santoro N; Putti MC; Micalizzi C; Zecca M; Cuccurullo R; Girardi K; Diverio D; Testi AM; Lo-Coco F; Locatelli F
Br J Haematol; 2019 Apr; 185(2):360-363. PubMed ID: 30028005
[No Abstract] [Full Text] [Related]
13. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
Garcia Spezza E; Brethon B; Petit A; Mazingue F; Gandemer V; Boissel N; Carausu L; Reguerre Y; Leverger G; Ducassou S
Br J Haematol; 2020 Jan; 188(1):170-173. PubMed ID: 31808943
[No Abstract] [Full Text] [Related]
14. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
15. AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
Lu J; Hu S; Wang W; Li J; Dong Z; Zhou J; Hai X
Toxicol Sci; 2018 Nov; 166(1):219-227. PubMed ID: 30376134
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
Cicconi L; Platzbecker U; Avvisati G; Paoloni F; Thiede C; Vignetti M; Fazi P; Ferrara F; Divona M; Albano F; Efficace F; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Annibali O; Wattad M; Lubbert M; Brandts CH; Hanel M; Rollig C; Schmitz N; Link H; Frairia C; Fozza C; Maria D'Arco A; Di Renzo N; Cortelezzi A; Fabbiano F; Dohner K; Ganser A; Dohner H; Amadori S; Mandelli F; Voso MT; Ehninger G; Schlenk RF; Lo-Coco F
Leukemia; 2020 Mar; 34(3):914-918. PubMed ID: 31611624
[No Abstract] [Full Text] [Related]
17. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
18. Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia.
Teran VA; Wilson BB; Guffey DJ
JAMA Dermatol; 2019 Mar; 155(3):389-391. PubMed ID: 30673070
[No Abstract] [Full Text] [Related]
19. Multiple Bowen's diseases and basal cell carcinomas in a patient with acute promyelocytic leukemia treated with arsenic trioxide: A case report and effective treatment with photodynamic therapy.
Ding C; Ma YY; Wang P; Liu J
Dermatol Ther; 2018 Nov; 31(6):e12718. PubMed ID: 30239071
[TBL] [Abstract][Full Text] [Related]
20. Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.
Rhee JY; Tremblay D; Chan AM; Tallman MS; Mascarenhas J
Blood Adv; 2019 Jun; 3(12):1854-1857. PubMed ID: 31213431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
